Pirarubicin Hydrochloride for Injection

This product is a semi-synthetic anthracycline anticancer drug. It enters the cell nucleus and quickly embeds into the DNA base pairs, interfering with the transcription process, preventing mRNA synthesis, inhibiting the activity of DNA polymerase and DNA topoisomerase Ⅱ (Topoisomerase Ⅱ, Topo Ⅱ), and interfering with DNA synthesis. Because this product interferes with DNA and mRNA synthesis at the same time, blocks the cell cycle in the G2 phase of cell division and inhibits tumor growth, it has strong anticancer activity.

This product is orange-red freeze-dried loose blocks or powder.

It is mainly suitable for respiratory tract infections and skin, soft tissue and bile tract infections caused by Staphylococcus aureus, hemolytic Streptococcus, Pneumococcus, etc., and can also be used for Mycoplasma pneumonia.

Dissolve this product in 10ml of 5% glucose injection or water for injection. It can be injected intravenously, intraarterially, or intravesically. Intravenous injection: generally 25-40mg/m2 per body surface area; arterial administration: such as head and neck cancer, 7-20mg/m2 per body surface area, once a day, for 5-7 days, or 14-25mg/m2 each time, once a week; intravesical administration: 15-30mg/m2 per body surface area, diluted to a concentration of 500-1000 μg/ml, injected into the bladder cavity and retained for 1-2 hours, 3 times a week as a course of treatment, 2-3 courses of treatment can be used.

1. Bone marrow suppression is a dose-limiting toxicity, mainly granulocytopenia, with an average minimum value of 14 days, recovery on the 21st day, and anemia and thrombocytopenia are rare; 2. Cardiac toxicity is lower than ADM, acute cardiotoxicity is mainly reversible ECG changes, such as arrhythmia or nonspecific ST-T abnormalities, and chronic cardiotoxicity is dose-accumulative; 3. Gastrointestinal reactions: nausea, vomiting, loss of appetite, oral mucositis, and sometimes diarrhea; 4. Others: abnormal liver and kidney function, hair loss, skin pigmentation, etc., and occasionally rash. Intravesical injection may cause bladder irritation symptoms such as frequent urination, painful urination, hematuria, and even bladder atrophy.

It is contraindicated for patients with severe organic heart disease or abnormal heart function and those who are allergic to this product; it is contraindicated for women during pregnancy, lactation and childbearing age.

20mg (calculated as C32H37NO12)